A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)

PURPOSE: Preclinical and clinical data have shown promise in using antiangiogenic agents to treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate the efficacy and toxicity of single‐agent pazopanib in patients with MPM. MATERIALS AND METHODS: Patients with MPM who...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncologist
Autors principals: Parikh, Kaushal, Mandrekar, Sumithra J., Allen‐Ziegler, Katie, Esplin, Brandt, Tan, Angelina D., Marchello, Benjamin, Adjei, Alex A., Molina, Julian R.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Inc. 2019
Matèries:
Lung Cancer
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288653/
https://ncbi.nlm.nih.gov/pubmed/31872928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0574
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars